Phoenix Asia Holdings Limited announced it will acquire 100% of ACEA Pharma, a clinical-stage pharmaceutical company, by issuing 100 million new shares valued at $1 billion. The acquisition is expected to close in Q2 2026, pending regulatory approvals including antitrust and Nasdaq clearance. Additionally, Phoenix Asia issued a $20 million convertible promissory note to its controlling shareholder as payment for advisory services. This marks Phoenix Asia's strategic shift from construction to becoming a pharmaceutical holding company.
Smart Clerk, an AI-powered bookkeeping platform, has surpassed 6,000 small business users who rely on its tools to simplify bookkeeping and generate tax-ready reports. The platform recently enhanced its connectivity by integrating with financial data...
The sulfuric acid market is projected to grow from $41.23 billion in 2025 to $49.94 billion by 2030 at a CAGR of 3.9%. Growth is driven by rising demand in metal processing, especially for base metals used in construction, electronics, and renewable ...
SpaceX shares have surged above $170 shortly after its IPO, surpassing two of three early analyst price targets. Initial targets ranged from $165 to $190, with the stock closing near $161 on the first day and rising to around $170 by the second day. ...
Tesla has been accused of presenting misleading safety data to European regulators to gain approval for its Full Self-Driving (FSD) system. Independent researchers and Reuters found that Tesla exaggerated its safety claims by using unrealistic assump...
On World Elder Abuse Awareness Day, First Federal Savings Bank and the Independent Community Bankers of America (ICBA) raised awareness about elder financial abuse, which involves billions in suspected losses annually. They shared practical tips to p...
